CTT Pharmaceutical Holdings, Inc. (OTC: CTTH), an innovative life sciences company with a portfolio of IP in novel drug delivery systems, today announced that it has entered into a business development partnership with 3 Rivers Biotech, a pre-eminent tissue culture company. Under the agreement, 3 Rivers will leverage its network of suppliers to and manufacturers of Consumer Packaged Goods (CPG) to secure commercial partnerships based on CTT's patented sublingual wafer technology.
Additionally, the agreement includes the ability for CTT to utilize 3 Rivers' operational capabilities to execute technology transfers and project implementation for new customers, providing a cost-efficient and de-risked expansion of CTT's operational capacity.
3 Rivers' is one of few companies with a successful track record in the consistent, commercial-scale supply of tissue-culture-based clones for a variety of sectors, including the hemp industry. As a trusted partner, 3 Rivers is very well positioned to engage in meaningful discussions within its network to explore the potential for commercial partnerships on behalf of CTT.
CTT's rapidly dissolving sublingual wafers deliver active ingredients through the buccal/mucosal route, which provides a number of key advantages over other delivery mechanisms, meeting important current market dynamics. These advantages offer CPG companies the opportunity to expand their portfolios with a well-differentiated, high-margin product offering on rapidly growing market segments.
Rapid onset CTT's strips dissolve quickly in the oral cavity (5-15 seconds), with the active ingredient rapidly absorbed into the bloodstream
Increased bioavailability the active ingredient, once absorbed, can bypass the liver's first-pass effect, improving therapeutic outcomes and efficacy through improved bioavailability
Safe smoke-free delivery bypassing lungs and digestive system
Ease of use taken orally, not requiring water or swallowing
Accurate and consistent dosing precisely determined and consistent potency of the active ingredient, a critical advantage over most other form factors
Increased adherence the ease of use and discrete administration can help increase positive adherence outcomes
Large target markets suitable for a wide range of applications in medical, wellness and recreational markets
Marc Lakmaaker, SVP Commercial Development for CTT, stated, "3 Rivers is a trusted partner at the root of the value chain for a growing number of companies in the CPG sector. Its network in large geographic markets, such as North America, China and Europe, creates a very significant opportunity for CTT to accelerate growth. The partnership also provides additional implementation bandwidth, which further de-risks our expansion efforts in a cost-effective manner."
Dr. Kevin Mehr, VP of Sales at 3 Rivers, added, "We believe that CTT's sublingual strips provide a unique and compelling commercial proposition for many companies in our network across a wide variety of sectors. The science behind CTT's technology, the effectiveness of its products, the Company's successful track record in bringing a new technology to market, and the caliber of its people, clearly differentiate CTT from its competition. We believe that these factors will greatly facilitate our ability to build new partnerships, and we look forward
